Nasdaq

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...
Nasdaq

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program REDWOOD CITY, ...
Yahoo

Low Blood Sugar Is Often Confused With Anxiety. Here's How To Spot It.

Maybe migraine attack symptoms are starting to creep in as you finish up work tasks before lunch. Or maybe after a long day, you can’t concentrate on the TV show you’re watching. You feel irritated ...
clinicaladvisor.com

Hypoglycemia in an ambulatory-care setting

Risk factors for hypoglycemia include mismatch of insulin timing, amount or type of carbohydrate intake, taking oral secretagogues without adequate carbohydrate intake, history of severe hypoglycemia, ...
Rolling Out

10 reasons your blood sugar drops dangerously low

Hypoglycemia occurs when blood sugar (glucose) levels fall below 70 milligrams per deciliter, creating a medical emergency that requires immediate treatment. The condition affects people with and ...
Seeking Alpha

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT) (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by ...